ID
45956
Description
Principal Investigator: Levi A. Garraway, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts and Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA MeSH: Carcinoma,Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000855 The purpose of the study was to compare gene expression profiles from a cohort of crizotinib-resistant ALK-rearranged lung tumors and a cohort of treatment-naive ALK-rearranged lung tumors. Expression profiles were generated by RNA-seq. In parallel, gene expression profiles were obtained from ALK-rearranged lung cancer cell lines in the presence or absence of the ALK inhibitor TAE684. Gene expression profiles were also obtained from ALK-rearranged cells ectopically expressing genes associated with ALK inhibitor resistance that were identified from a functional genetic study.
Lien
Mots-clés
Versions (2)
- 15/03/2024 15/03/2024 - Dr. Christian Niklas
- 16/03/2024 16/03/2024 - Madita Rudolph
Détendeur de droits
Levi A. Garraway, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts and Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA
Téléchargé le
16 mars 2024
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs000855 Resistance studies in Lung Cancer
Sample ID, sample type [tumor], and analyte type of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID, sample ID, and sample use variable obtained from participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID and sext of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Sample ID, sample type [tumor], and analyte type of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
Similar models
Sample ID, sample type [tumor], and analyte type of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID, sample ID, and sample use variable obtained from participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID and sext of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Sample ID, sample type [tumor], and analyte type of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
C1299222 (UMLS CUI [1,2])
C2347026 (UMLS CUI [1,2])
C0475752 (UMLS CUI [1,3])
C0205307 (UMLS CUI [1,4])
C0449438 (UMLS CUI [1,5])